International Intracranial Dissection Study
Launched by INSEL GRUPPE AG, UNIVERSITY HOSPITAL BERN · Apr 28, 2016
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The International Intracranial Dissection Study is a clinical trial aimed at better understanding intracranial artery dissection, a condition that can lead to serious issues like stroke, especially in young adults. This study seeks to find out how often these dissections occur, what the best treatments might be, and what factors influence recovery. Currently, there's not enough information about this condition, particularly regarding its effects on non-Asian patients, and the trial aims to gather more evidence by closely studying a larger group of patients.
To participate in this study, individuals must be at least 18 years old and have experienced symptoms of an intracranial artery dissection within the last 30 days. Participants will undergo standardized tests and follow-up procedures to help researchers collect consistent and reliable data. This research is important because it could lead to better management and treatment for patients facing this serious condition. If you or a loved one is eligible, joining the study could contribute to advancements in understanding and treating this condition.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with acute Intracranial Artery Dissection (symptom onset ≤ 30 days)
- • Age ≥ 18 years
- • Consent to participate according to local requirements
- Exclusion Criteria:
- • Iatrogenic dissection caused by endovascular intervention
- • Extracranial dissection with intracranial extension
About Insel Gruppe Ag, University Hospital Bern
Insel Gruppe AG, the umbrella organization for the University Hospital Bern, is a leading healthcare provider in Switzerland, renowned for its commitment to advancing medical research and patient care. As a key player in clinical trials, Insel Gruppe AG integrates cutting-edge scientific inquiry with clinical excellence, facilitating innovative studies that span a wide range of medical disciplines. The institution prioritizes collaboration with academic partners and industry stakeholders to enhance the understanding of diseases and develop effective treatment options, ultimately aiming to improve patient outcomes and contribute to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Osaka, Kansai, Japan
Basel, Basel Stadt, Switzerland
Bern, , Switzerland
Patients applied
Trial Officials
Marcel Arnold, Prof. Dr. med.
Principal Investigator
Neurology Department, Inselspital University Hospital Bern
Barbara Goeggel Simonetti, Dr. med.
Principal Investigator
Neurology Department, Inselspital University Hospital Bern
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials